SANUWAVE Takes Next Step in Wound Care Expansion
DERMAPACE TECHNOLOGY SUGGESTS PROMISING OUTCOMES OF ACOUSTIC PRESSURE SHOCKWAVE TREATMENT FOR VENOUS LEG ULCERS (VLU)
GLOBAL VLU MARKET SIZE SIMILAR TO DFU
SUWANEE, GA – (NewMediaWire) – March 08, 2018 – SANUWAVE Health, Inc. (OTCQB: SNWV), an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, announces the publication of research that investigated the use of the dermaPACE® System in the treatment of Venous Leg Ulcers (VLU) in a case study series. The study, titled “Treating venous leg ulcers with Extracorporeal Shockwave Technology (ESWT)” by Charne Miller (LaTrobe University), Suzanne Kapp (University of Melbourne), Jade Green (LaTrobe University), William McGuiness (LaTrobe Alfred Health Clinical School), and Michael Woodward (Austin Health/University of Melbourne), appeared in Wounds International 2017, Volume 8 Issue 3. The case series was implemented at a medical professional lead, multidisciplinary outpatient wound clinic in Melbourne, Australia.
The case study series consisted of 6 patients, meeting eligibility criteria, presenting with venous leg ulcers (VLU) and who agreed to receive the dermaPACE treatment. In order to better understand wound response to dose and energy, treatment selection used the two highest energy settings on the dermaPACE System, delivered at a frequency of 240 pulses/min. The shockwave pulse count was a function of wound area (cm2) with larger wounds requiring more shockwaves for treatment and thus longer time per therapy session than smaller wounds. The protocol used recommended one treatment delivered each week for 10 weeks.
Positive wound healing effects were observed for the majority of patients receiving ESWT. At the conclusion of the case series the majority of wounds were either healed or healing was anticipated in a subsequent visit.
For the full release please go to: